Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 6

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 6
---
 with, the more detailed information appearing elsewhere in this prospectus supplement, the accompanying base prospectus, any applicable free writing prospectus and the documents incorporated by reference herein and therein. You should read all such documents carefully, especially the risk factors included in this prospectus and our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such risk factors may be amended, updated or modified periodically in our quarterly reports filed on Form 10-Q with the SEC, and any amendment or update thereto reflected in subsequent filings with the SEC and incorporated by reference in this prospectus, and our consolidated financial statements and the related notes included or incorporated by reference herein or therein, before deciding to buy shares of our common stock. Unless the context requires otherwise, references in this prospectus supplement to “SXTP,” “we,” “us,” and “our” refer to 60 Degree Pharmaceuticals, Inc.

Company Overview

Overview

Our Business

We are a specialty pharmaceutical company with
a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention
and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that
has been on the market since late 2019. Currently, 60P’s pipeline under development covers development programs for vector-borne,
fungal, and viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of
Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir/extracts of Australian Chestnut trees.

Mission

Our mission is to address the unmet medical need
associated with infectious diseases through the development and commercialization of new small molecule therapeutics, focusing on synthetic
drugs (made by chemists in labs, excluding biologics) with good safety profiles based on prior clinical studies, in order to reduce cost,
risk, and capitalize on existing research. We are seeking to expand Arakoda’s use beyond malaria prevention and to demonstrate clinical
benefit for other disease indications. We are further assessing the feasibility of moving other products forward for various indications.

Market Opportunity

Malaria Prevention

In 2018, the FDA approved Arakoda for malaria
prevention in individuals 18 years and older. Arakoda entered the U.S. supply chain in the third quarter of 2019, just prior to the COVID-19